• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

澳大利亚因肝硬化住院患者病因因素和合并症的流行率变化。

Changing prevalence of aetiological factors and comorbidities among Australians hospitalised for cirrhosis.

机构信息

Population Health Department, QIMR Berghofer Medical Research Institute, Brisbane, Queensland, Australia.

Centre for Liver Disease Research, Translational Research Institute, Faculty of Medicine, The University of Queensland, Brisbane, Queensland, Australia.

出版信息

Intern Med J. 2021 May;51(5):691-698. doi: 10.1111/imj.14809.

DOI:10.1111/imj.14809
PMID:32096890
Abstract

BACKGROUND

The rate of hospital admissions for cirrhosis increased 1.3-fold during 2008-2016 in Queensland. Alcohol misuse was a contributing factor for cirrhosis in 55% of admissions and 40% of patients had at least one comorbidity.

AIMS

To examine the temporal change in aetiology of liver disease and presence of comorbidity in patients admitted with cirrhosis.

METHODS

Population-based retrospective cohort study of all people treated in hospital for cirrhosis (10 254 patients) in Queensland during 2008-2016. Data were sourced from Queensland Hospital Admitted Patient Data Collection.

RESULTS

The commonest aetiology was alcohol (49.5%), followed by cryptogenic (unspecified cirrhosis; 28.5%), hepatitis C virus (19.3%), non-alcoholic fatty liver disease (NAFLD)/non-alcoholic steatohepatitis (NASH) (4.8%) and hepatitis B virus (HBV) (4.3%). The prevalence of alcohol-related (P = 0.41) and hepatitis C virus (P = 0.08) remained stable between 2008-2010 and 2014-2016, that of NAFLD/NASH, cryptogenic and HBV-cirrhosis increased by 67% (P < 0.00001), 27% (P < 0.00001) and 20% (P = 0.00019), respectively; 41.1% of patients had at least one comorbidity. The prevalence of type 2 diabetes nearly doubled (from 13.7% to 25.4%; P < 0.00001) between 2008-2010 and 2014-2016.

CONCLUSIONS

Alcohol misuse was the most important aetiology. The importance of NAFLD/NASH, cryptogenic and HBV-cirrhosis and the burden of comorbidity increased during 2008-2016. Ongoing alcohol misuse and the increasing prevalence of NAFLD/NASH, cryptogenic cirrhosis and comorbid type 2 diabetes among admissions for cirrhosis has implications for public health interventions to reduce the burden of unhealthy lifestyle and metabolic disorders.

摘要

背景

2008 年至 2016 年期间,昆士兰州因肝硬化住院的人数增加了 1.3 倍。酒精滥用是导致 55%肝硬化患者入院的一个因素,40%的患者至少有一种合并症。

目的

研究肝硬化患者入院时病因和合并症的时间变化。

方法

这是一项基于人群的回顾性队列研究,对 2008 年至 2016 年期间在昆士兰州因肝硬化住院治疗的所有人(10254 名患者)进行研究。数据来源于昆士兰医院住院患者数据采集。

结果

最常见的病因是酒精(49.5%),其次是不明原因(未特指的肝硬化;28.5%)、丙型肝炎病毒(19.3%)、非酒精性脂肪性肝病(NAFLD)/非酒精性脂肪性肝炎(NASH)(4.8%)和乙型肝炎病毒(HBV)(4.3%)。2008-2010 年和 2014-2016 年之间,酒精相关(P = 0.41)和丙型肝炎病毒(P = 0.08)的患病率保持稳定,而 NASH、不明原因和 HBV 肝硬化的患病率分别增加了 67%(P < 0.00001)、27%(P < 0.00001)和 20%(P = 0.00019);41.1%的患者至少有一种合并症。2008-2010 年和 2014-2016 年之间,2 型糖尿病的患病率几乎翻了一番(从 13.7%增加到 25.4%;P < 0.00001)。

结论

酒精滥用是最重要的病因。2008-2016 年期间,NAFLD/NASH、不明原因和 HBV 肝硬化的重要性以及合并症的负担增加。肝硬化患者中持续的酒精滥用以及 NAFLD/NASH、不明原因肝硬化和合并 2 型糖尿病的患病率增加,对减少不健康生活方式和代谢紊乱负担的公共卫生干预措施具有重要意义。

相似文献

1
Changing prevalence of aetiological factors and comorbidities among Australians hospitalised for cirrhosis.澳大利亚因肝硬化住院患者病因因素和合并症的流行率变化。
Intern Med J. 2021 May;51(5):691-698. doi: 10.1111/imj.14809.
2
Prevalence of Nonalcoholic Steatohepatitis-Associated Cirrhosis in the United States: An Analysis of National Health and Nutrition Examination Survey Data.美国非酒精性脂肪性肝炎相关肝硬化的患病率:基于国家健康与营养检查调查数据的分析
Am J Gastroenterol. 2017 Apr;112(4):581-587. doi: 10.1038/ajg.2017.5. Epub 2017 Feb 14.
3
The conundrum of cryptogenic cirrhosis: Adverse outcomes without treatment options.隐匿性肝硬化的难题:无治疗选择的不良结局。
J Hepatol. 2018 Dec;69(6):1365-1370. doi: 10.1016/j.jhep.2018.08.013. Epub 2018 Aug 23.
4
Chronic liver disease in diabetes mellitus.糖尿病中的慢性肝病
Trop Gastroenterol. 2002 Jan-Mar;23(1):3-5.
5
Incidence, aetiology and related comorbidities of cirrhosis: a Swedish population-based cohort study.肝硬化的发病率、病因学及相关合并症:一项瑞典基于人群的队列研究。
BMC Gastroenterol. 2020 Apr 3;20(1):84. doi: 10.1186/s12876-020-01239-6.
6
High prevalence of diabetes among young First Nations Peoples with metabolic dysfunction-associated steatotic liver disease: a population-based study in Australia.高患病率的糖尿病在代谢功能障碍相关脂肪性肝病的年轻原住民人群中:澳大利亚的一项基于人群的研究。
Int J Equity Health. 2024 Apr 30;23(1):84. doi: 10.1186/s12939-024-02153-z.
7
Modeling NAFLD disease burden in China, France, Germany, Italy, Japan, Spain, United Kingdom, and United States for the period 2016-2030.建立中国、法国、德国、意大利、日本、西班牙、英国和美国 2016-2030 年非酒精性脂肪性肝病疾病负担模型。
J Hepatol. 2018 Oct;69(4):896-904. doi: 10.1016/j.jhep.2018.05.036. Epub 2018 Jun 8.
8
Increasing Prevalence and High Survival Rate of Liver Transplanted Patients with NASH and PSC Cirrhosis.非酒精性脂肪性肝炎(NASH)和原发性胆汁性胆管炎(PSC)肝硬化肝移植患者的患病率上升及高生存率
Arch Iran Med. 2024 Jan 1;27(1):23-29. doi: 10.34172/aim.2024.04.
9
NASH Is the Most Rapidly Growing Etiology for Acute-on-Chronic Liver Failure-Related Hospitalization and Disease Burden in the United States: A Population-Based Study.NASH 是导致美国急性加重慢性肝衰竭相关住院和疾病负担增长最快的病因:一项基于人群的研究。
Liver Transpl. 2019 May;25(5):695-705. doi: 10.1002/lt.25443.
10
Nonalcoholic fatty liver disease progression rates to cirrhosis and progression of cirrhosis to decompensation and mortality: a real world analysis of Medicare data.非酒精性脂肪性肝病向肝硬化的进展率及肝硬化向失代偿和死亡率的进展:医疗保险数据的真实世界分析。
Aliment Pharmacol Ther. 2020 Jun;51(11):1149-1159. doi: 10.1111/apt.15679. Epub 2020 May 5.

引用本文的文献

1
The unwell patient with advanced chronic liver disease: when to use each score?患有晚期慢性肝病的不适患者:何时使用每种评分?
BMC Med. 2025 Jul 9;23(1):413. doi: 10.1186/s12916-025-04185-w.
2
A Nonrandomized Pilot Study to Investigate the Acceptability and Feasibility of LivR Well: A Multifaceted 28-Day Home-Based Liver Optimization Program for Acute-on-Chronic Liver Failure.一项非随机试点研究,旨在调查LivR Well的可接受性和可行性:一项针对慢性肝衰竭急性发作的为期28天的多方面居家肝脏优化计划。
Gastro Hep Adv. 2024 Oct 18;4(2):100567. doi: 10.1016/j.gastha.2024.10.007. eCollection 2025.
3
Trends in viral hepatitis liver-related morbidity and mortality in New South Wales, Australia.
澳大利亚新南威尔士州病毒性肝炎肝脏相关发病率和死亡率的趋势。
Lancet Reg Health West Pac. 2024 Aug 31;51:101185. doi: 10.1016/j.lanwpc.2024.101185. eCollection 2024 Oct.
4
Trends in the burden of hospitalised patients with cirrhosis in Switzerland: a cross-sectional study of cirrhosis-related hospitalisations between 1998 and 2020.瑞士肝硬化住院患者负担的变化趋势:1998 年至 2020 年期间肝硬化相关住院治疗的横断面研究。
BMJ Open. 2024 Aug 24;14(8):e081822. doi: 10.1136/bmjopen-2023-081822.
5
High prevalence of diabetes among young First Nations Peoples with metabolic dysfunction-associated steatotic liver disease: a population-based study in Australia.高患病率的糖尿病在代谢功能障碍相关脂肪性肝病的年轻原住民人群中:澳大利亚的一项基于人群的研究。
Int J Equity Health. 2024 Apr 30;23(1):84. doi: 10.1186/s12939-024-02153-z.
6
Changing Prevalence of Medication Use in People with Cirrhosis: A Retrospective Cohort Study Using Pharmaceutical Benefits Scheme Data.肝硬化患者药物使用流行率的变化:一项使用药品福利计划数据的回顾性队列研究
Drugs Real World Outcomes. 2023 Dec;10(4):605-618. doi: 10.1007/s40801-023-00390-2. Epub 2023 Oct 13.
7
The Hidden Epidemic: The Prevalence and Impact of Concurrent Liver Diseases in Patients Undergoing Liver Transplantation in Australia and New Zealand.隐匿性流行病:澳大利亚和新西兰肝移植患者中并发肝病的患病率及影响
Transplant Direct. 2022 Jul 15;8(8):e1345. doi: 10.1097/TXD.0000000000001345. eCollection 2022 Aug.
8
Acute-on-chronic liver failure: Controversies and consensus.急性慢性肝衰竭:争议与共识。
World J Gastroenterol. 2023 Jan 14;29(2):232-240. doi: 10.3748/wjg.v29.i2.232.
9
Trends in decompensated cirrhosis and hepatocellular carcinoma among people with a hepatitis B notification in New South Wales.新南威尔士州乙肝报告人群中失代偿期肝硬化和肝细胞癌的发病趋势
JHEP Rep. 2022 Aug 6;4(10):100552. doi: 10.1016/j.jhepr.2022.100552. eCollection 2022 Oct.
10
A home-based, multidisciplinary liver optimisation programme for the first 28 days after an admission for acute-on-chronic liver failure (LivR well): a study protocol for a randomised controlled trial.一项针对急性加重期慢性肝衰竭患者入院后 28 天内的家庭为基础的多学科肝脏优化方案(LivR well):一项随机对照试验的研究方案。
Trials. 2022 Sep 5;23(1):744. doi: 10.1186/s13063-022-06679-x.